Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedNov 14, 2025
DataAggregated Company Financials
Companies544
  • 7D5.1%
  • 3M17.1%
  • 1Y17.1%
  • YTDn/a

Over the last 7 days, the Biotech industry has risen 5.1%, driven by gains from AbbVie of 6.2%. In the last 12 months, the industry was up 17%. Earnings are forecast to grow by 24% annually.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 18 Nov 2025US$1.2tUS$163.8b-US$16,256,883,029.7417.8x-73.3x7.3x
Thu, 16 Oct 2025US$1.1tUS$163.4b-US$18,204,675,258.7617.2x-62.9x7x
Sat, 13 Sep 2025US$1.1tUS$163.6b-US$18,371,646,878.7815.3x-59.4x6.7x
Mon, 11 Aug 2025US$1.0tUS$163.2b-US$15,518,415,597.7813.7x-65.7x6.3x
Wed, 09 Jul 2025US$946.8bUS$155.8b-US$23,411,363,591.5817.3x-40.4x6.1x
Fri, 06 Jun 2025US$931.0bUS$155.9b-US$23,959,451,458.7016.2x-38.9x6x
Sun, 04 May 2025US$959.8bUS$153.8b-US$24,601,947,084.6619.7x-39x6.2x
Tue, 01 Apr 2025US$817.0bUS$118.6b-US$36,943,209,502.2323.8x-22.1x6.9x
Thu, 27 Feb 2025US$846.4bUS$117.5b-US$37,773,216,777.4217.1x-22.4x7.2x
Sat, 25 Jan 2025US$989.8bUS$149.5b-US$26,320,970,275.6817.2x-37.6x6.6x
Mon, 23 Dec 2024US$956.2bUS$149.9b-US$26,389,992,070.3815.7x-36.2x6.4x
Wed, 20 Nov 2024US$990.2bUS$150.0b-US$26,773,675,559.7217.2x-37x6.6x
Fri, 18 Oct 2024US$914.8bUS$113.1b-US$35,984,216,716.8621.7x-25.4x8.1x
Sun, 15 Sep 2024US$932.2bUS$113.2b-US$36,059,145,110.5923.4x-25.9x8.2x
Tue, 13 Aug 2024US$862.5bUS$112.7b-US$36,817,276,448.4121.6x-23.4x7.7x
Thu, 11 Jul 2024US$1.2tUS$164.5b-US$28,073,053,814.9128.5x-41.1x7x
Sat, 08 Jun 2024US$1.2tUS$164.5b-US$26,778,554,526.2628.1x-43.3x7x
Mon, 06 May 2024US$1.1tUS$163.7b-US$26,731,775,868.3424.3x-42x6.9x
Wed, 03 Apr 2024US$1.2tUS$164.3b-US$23,551,987,061.8123.5x-49.8x7.1x
Fri, 01 Mar 2024US$1.2tUS$167.8b-US$21,392,405,891.3015.9x-56x7.1x
Sun, 28 Jan 2024US$1.4tUS$204.7b-US$22,652,938,045.0018.3x-63.1x7x
Tue, 26 Dec 2023US$1.4tUS$204.9b-US$22,199,973,627.0019.4x-61.8x6.7x
Thu, 23 Nov 2023US$1.2tUS$204.7b-US$22,048,392,183.0017.9x-55.5x6x
Sat, 21 Oct 2023US$1.2tUS$207.4b-US$13,088,260,702.0016.6x-93.6x5.9x
Mon, 18 Sep 2023US$1.3tUS$207.5b-US$12,865,929,372.0017.5x-99.8x6.2x
Wed, 16 Aug 2023US$1.3tUS$207.7b-US$12,305,774,462.0018x-104.4x6.2x
Fri, 14 Jul 2023US$1.1tUS$186.7b-US$15,961,677,744.0013.2x-70.8x6.1x
Sun, 11 Jun 2023US$1.1tUS$186.0b-US$15,970,598,297.0011.7x-71.6x6.1x
Tue, 09 May 2023US$1.2tUS$192.6b-US$12,055,565,323.0015.7x-96.6x6x
Thu, 06 Apr 2023US$1.2tUS$216.9b-US$5,780,676,383.0014.8x-199.9x5.3x
Sat, 04 Mar 2023US$1.2tUS$199.0b-US$4,941,026,359.0016.5x-233.1x5.8x
Mon, 30 Jan 2023US$1.2tUS$203.8bUS$1.8b14.8x662.7x5.7x
Wed, 28 Dec 2022US$1.1tUS$203.3bUS$1.7b14.1x680.9x5.6x
Fri, 25 Nov 2022US$1.1tUS$202.3bUS$1.3b14.6x844.9x5.6x
Price to Earnings Ratio

844.9x


Total Market Cap: US$1.1tTotal Earnings: US$1.3bTotal Revenue: US$202.3bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average 14.8x202320242025
Current Industry PE
  • Investors are optimistic on the American Biotechnology industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 6.5x is lower than the industry's current PS ratio of 7.3x.
Past Earnings Growth
  • Total earnings for the Biotechnology industry have declined over the last three years, with the industry now making a loss overall.
  • Revenues have also declined 6.8% per year, which is driving profits down.

Industry Comparison

How does U.S. Biotech compare with similar industries?

US Market-0.39%
Healthcare3.77%
Biotech5.08%
Biotech5.08%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ABBV AbbVieUS$234.007.0%
+US$27.0b		40.7%PE176.1x
AMGN AmgenUS$341.715.6%
+US$9.7b		22.6%PE26.3x
GILD Gilead SciencesUS$124.095.0%
+US$7.4b		40.3%PE19x
ONC BeOne MedicinesUS$376.6314.4%
+US$5.2b		100.7%PE608x
REGN Regeneron PharmaceuticalsUS$704.317.6%
+US$5.1b		-7.6%PE15.8x

Latest News

ABBV
US$234.00
AbbVie
7D
7.0%
1Y
40.7%
ONC
US$376.63
BeOne Medicines
7D
14.4%
1Y
100.7%
INCY
US$104.17
Incyte
7D
-1.7%
1Y
35.3%
CDTX
US$217.91
Cidara Therapeutics
7D
110.0%
1Y
1,356.6%
AMGN
US$341.71
Amgen
7D
5.6%
1Y
22.6%

AMGN: Future Pipeline Progress And Profit Margins Will Guide Near-Term Performance

Amgen's fair value target has increased by approximately $7 to $318.51, as analysts highlight robust profit margin improvement and sustained pipeline progress in their latest updates. Analyst Commentary Recent updates from Wall Street reveal a mix of optimism and caution surrounding Amgen’s outlook.
ROIV
US$20.56
Roivant Sciences
7D
-2.9%
1Y
84.2%

ROIV: Upcoming Data From Phase 3 Trials Will Drive Shares Higher

Analysts have raised their fair value estimate for Roivant Sciences from $20.86 to $23.27 per share. They cite strong Phase 3 trial results, continued clinical progress, and anticipated upcoming catalysts as key factors behind the updated price target.
VRTX
US$434.02
Vertex Pharmaceuticals
7D
3.0%
1Y
-7.1%
GILD
US$124.09
Gilead Sciences
7D
5.0%
1Y
40.3%
LEGN
US$29.72
Legend Biotech
7D
-5.9%
1Y
-20.6%
ALNY
US$460.54
Alnylam Pharmaceuticals
7D
4.3%
1Y
98.3%
BNTX
US$102.67
BioNTech
7D
-2.3%
1Y
0.8%
ALKS
US$29.33
Alkermes
7D
-10.2%
1Y
6.5%
REGN
US$704.31
Regeneron Pharmaceuticals
7D
7.6%
1Y
-7.6%
NBIX
US$143.56
Neurocrine Biosciences
7D
-4.3%
1Y
22.1%
SMMT
US$16.95
Summit Therapeutics
7D
-7.4%
1Y
-10.7%
MENS
US$30.72
Jyong Biotech
7D
-20.7%
1Y
n/a